From the Guidelines
Mirabegron (Myrbetriq) is contraindicated in patients with severe uncontrolled hypertension. This is based on the most recent evidence from the 2023 European Association of Urology guidelines on the management of non-neurogenic male lower urinary tract symptoms 1. The guidelines highlight that mirabegron is well tolerated in the elderly and in patients with multiple comorbidities, but its use is contraindicated in patients with severe uncontrolled hypertension due to the potential to increase blood pressure.
Some key points to consider when prescribing mirabegron include:
- The most frequent adverse events (AEs) associated with mirabegron are hypertension, UTIs, headache, and nasopharyngitis 1
- Mirabegron does not affect voiding urodynamic parameters, and the overall change in post-void residual (PVR) is small 1
- Long-term data on the efficacy and safety of mirabegron in men of any age with LUTS are not available, which should be taken into consideration when prescribing this medication
It is essential to carefully evaluate patients for any contraindications before initiating mirabegron therapy, particularly severe uncontrolled hypertension, to minimize the risk of adverse events and ensure optimal treatment outcomes.
From the FDA Drug Label
Mirabegron extended-release tablets are contraindicated in patients with known hypersensitivity reactions to mirabegron or any inactive ingredients of the tablet [see Adverse Reactions (6.1,6.2)]. Hypersensitivity to mirabegron or any inactive ingredients. (4) Mirabegron extended-release tablets are contraindicated in patients with known hypersensitivity reactions to mirabegron or any inactive ingredients of the tablet [see Adverse Reactions (6.1,6.2)].
The contraindications to Myrbetriq (Mirabegron) are:
- Hypersensitivity to mirabegron or any inactive ingredients of the tablet 2
- Known hypersensitivity reactions to mirabegron or any inactive ingredients 2
- Hypersensitivity to mirabegron or any inactive ingredients 2
From the Research
Contraindications to Myrbetriq (Mirabegron)
- Severe uncontrolled hypertension is a contraindication to Myrbetriq (Mirabegron) 3
Definition of Severe Uncontrolled Hypertension
- Severe uncontrolled hypertension is defined as a systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥110 mm Hg 3